CSIMarket
 


Respirerx Pharmaceuticals Inc   (RSPI)
Other Ticker:  
 
 

RSPI's Income from Cont. Operations Growth by Quarter and Year

Respirerx Pharmaceuticals Inc 's Income from Cont. Operations results by quarter and year




RSPI Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -0.64 -0.40 -1.06
III Quarter September - -1.64 -1.09 -1.48
II Quarter June -0.69 -0.83 -0.81 -0.82
I Quarter March -0.43 -0.86 -0.85 -0.95
FY   -1.12 -3.97 -3.15 -4.31



RSPI Income from Cont. Operations second quarter 2023 Y/Y Growth Comment
Respirerx Pharmaceuticals Inc in the second quarter 2023 recorded loss from continued operations of $ -0.69 millions.

According to the results reported in the second quarter 2023, Respirerx Pharmaceuticals Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Respirerx Pharmaceuticals Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the second quarter 2023.




RSPI Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Respirerx Pharmaceuticals Inc 's second quarter 2023 Income from Cont. Operations $ -0.69 millions RSPI's Income Statement
Respirerx Pharmaceuticals Inc 's second quarter 2022 Income from Cont. Operations $ -0.83 millions Quarterly RSPI's Income Statement
New: More RSPI's historic Income from Cont. Operations Growth >>


RSPI Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Respirerx Pharmaceuticals Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RSPI's II. Quarter Q/Q Income from Cont. Operations Comment
Current loss from continued operations of -0.69 millions by Respirerx Pharmaceuticals Inc come out even more unfavourable compare to the -0.43 millions loss from continued operations in the previous quarter.

Within Major Pharmaceutical Preparations industry Respirerx Pharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While Respirerx Pharmaceuticals Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RSPI's II. Quarter Q/Q Income from Cont. Operations Comment
Recent accomplishment of -0.69 millions by Respirerx Pharmaceuticals Inc appear even less good compare to the loss from continued operations -0.43 millions in the first quarter.

Within Major Pharmaceutical Preparations industry Respirerx Pharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While Respirerx Pharmaceuticals Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Respirerx Pharmaceuticals Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -3.40 $ -3.54 $ -3.97 $ -3.73 $ -3.17
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Respirerx Pharmaceuticals Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -3 millions in the Jun 30 2023 period.

Respirerx Pharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Respirerx Pharmaceuticals Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -3 millions in the Jun 30 2023 period.

Respirerx Pharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
RSPI's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for RSPI's Competitors
Income from Cont. Operations Growth for Respirerx Pharmaceuticals Inc 's Suppliers
Income from Cont. Operations Growth for RSPI's Customers

You may also want to know
RSPI's Annual Growth Rates RSPI's Profitability Ratios RSPI's Asset Turnover Ratio RSPI's Dividend Growth
RSPI's Roe RSPI's Valuation Ratios RSPI's Financial Strength Ratios RSPI's Dividend Payout Ratio
RSPI's Roa RSPI's Inventory Turnover Ratio RSPI's Growth Rates RSPI's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Jun 30 2023
Corcept Therapeutics Inc-0.15%$ -0.153 millions
Quest Diagnostics Inc-0.40%$ -0.400 millions
Align Technology inc -0.87%$ -0.874 millions
Adapthealth Corp -1.35%$ -1.351 millions
U S Physical Therapy Inc-2.57%$ -2.569 millions
Prestige Consumer Healthcare Inc -3.31%$ -3.313 millions
Pediatrix Medical Group Inc -7.88%$ -7.879 millions
Dariohealth Corp -8.00%$ -8.004 millions
Gilead Sciences Inc -8.46%$ -8.458 millions
Acadia Healthcare Company Inc -10.23%$ -10.232 millions
National Research Corporation-12.61%$ -12.605 millions
Davita Inc -13.44%$ -13.435 millions
Biomx Inc -14.31%$ -14.314 millions
Viatris Inc -15.90%$ -15.897 millions
West Pharmaceutical Services Inc -17.72%$ -17.719 millions
Carlisle Companies Incorporated-18.38%$ -18.385 millions
Chemed Corporation-19.68%$ -19.681 millions
Sotera Health Company-22.70%$ -22.700 millions
Edwards Lifesciences Corporation-24.83%$ -24.828 millions
Royalty Pharma Plc-28.53%$ -28.532 millions
Atrion Corporation-29.79%$ -29.792 millions
Abbott Laboratories-31.86%$ -31.863 millions
Orgenesis Inc -33.34%$ -33.339 millions
Hh and l Acquisition Co -33.56%$ -33.559 millions
Organogenesis Holdings Inc -39.20%$ -39.204 millions
Fonar Corporation-40.34%$ -40.343 millions
Vanda Pharmaceuticals Inc -40.95%$ -40.948 millions
Biogen Inc -43.96%$ -43.960 millions
Lftd Partners Inc -48.46%$ -48.455 millions
Laboratory Corporation Of America Holdings-56.76%$ -56.757 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com